2025
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial
O’Malley S, Miranda R, Book S, Chun T, Liss T, Malcolm R, Muvvala S, Padovano H, Schacht J, Blackburn B, Diamond I, Ransom J, Ryan M, Falk D, Litten R. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol And Alcoholism 2025, 60: agaf001. PMID: 39829301, PMCID: PMC11744046, DOI: 10.1093/alcalc/agaf001.Peer-Reviewed Original ResearchAlcohol use disorderAldehyde dehydrogenase 2 inhibitorUse disorderTreat alcohol use disorderCue reactivity sessionsCue-elicited cravingCue-induced cravingHuman laboratory studiesTreatment-seeking adultsAlcohol use disorder pharmacotherapiesAldehyde dehydrogenase 2Multisite clinical trialDose to placeboWeeks of medicationEffect size estimatesReactivation sessionDrinking outcomesGroup differencesCravingMeasured 1 weekEffect sizeCohen's dDouble-blindPreliminary effectivenessAlcohol consumption
2020
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
Miranda R, O’Malley S, Padovano H, Wu R, Falk DE, Ryan ML, Fertig JB, Chun TH, Muvvala SB, Litten RZ. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline. Alcohol Clinical And Experimental Research 2020, 44: 1431-1443. PMID: 32363592, PMCID: PMC7572549, DOI: 10.1111/acer.14352.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol cue reactivityClinical trialsCue-reactivity paradigmAlcohol useCue reactivityUse disordersHuman laboratoryAlcohol cue-induced cravingSubsequent treatment outcomesΑ4β2 nicotinic acetylcholine receptorsCue-induced alcoholAlcohol cue reactivity paradigmCue-induced cravingNicotinic acetylcholine receptorsHeavy alcohol useCue-elicited cravingHuman laboratory paradigmTreatment outcomesVareniclinePlaceboProspective associationsAlcohol cravingAcetylcholine receptors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply